Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Sep;76(9):1217–1221. doi: 10.1136/jnnp.2004.057893

Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation

R Hilker 1, A Portman 1, J Voges 1, M Staal 1, L Burghaus 1, T van Laar 1, A Koulousakis 1, R Maguire 1, J Pruim 1, B M de Jong 1, K Herholz 1, V Sturm 1, W Heiss 1, K Leenders 1
PMCID: PMC1739814  PMID: 16107354

Abstract

Objectives: Glutamate mediated excitotoxicity of the hyperactive subthalamic nucleus (STN) has been reported to contribute to nigral degeneration in Parkinson's disease (PD). Deep brain stimulation of the STN (STN DBS), in its role as a highly effective treatment of severe PD motor complications, has been thought to inhibit STN hyperactivity and therefore decrease progression of PD.

Methods: In a prospective two centre study, disease progression was determined by means of serial 18F-fluorodopa (F-dopa) positron emission tomography (PET) in 30 patients with successful STN DBS over the first 16 (SD 6) months after surgery.

Results: Depending on the method of PET data analysis used in the two centres, annual progression rates relative to baseline were 9.5–12.4% in the caudate and 10.7–12.9% in the putamen.

Conclusions: This functional imaging study is the first to demonstrate a continuous decline of dopaminergic function in patients with advanced PD under clinically effective bilateral STN stimulation. The rates of progression in patients with STN DBS were within the range of previously reported data from longitudinal imaging studies in PD. Therefore this study could not confirm the neuroprotective properties of DBS in the STN target.

Full Text

The Full Text of this article is available as a PDF (85.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashkan K., Wallace B., Bell B. A., Benabid A. L. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? Br J Neurosurg. 2004 Feb;18(1):19–34. doi: 10.1080/02688690410001660427. [DOI] [PubMed] [Google Scholar]
  2. Benabid A. L., Koudsie A., Benazzouz A., Piallat B., Krack P., Limousin-Dowsey P., Lebas J. F., Pollak P. Deep brain stimulation for Parkinson's disease. Adv Neurol. 2001;86:405–412. [PubMed] [Google Scholar]
  3. Benazzouz A., Piallat B., Ni Z. G., Koudsie A., Pollak P., Benabid A. L. Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease. Cell Transplant. 2000 Mar-Apr;9(2):215–221. doi: 10.1177/096368970000900207. [DOI] [PubMed] [Google Scholar]
  4. Brooks D. J. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl. 2000;(60):125–137. doi: 10.1007/978-3-7091-6301-6_8. [DOI] [PubMed] [Google Scholar]
  5. Defer G. L., Widner H., Marié R. M., Rémy P., Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord. 1999 Jul;14(4):572–584. doi: 10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Dhawan Vijay, Ma Yilong, Pillai Vandhana, Spetsieris Phoebe, Chaly Thomas, Belakhlef Abdelfatihe, Margouleff Claude, Eidelberg David. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med. 2002 Oct;43(10):1324–1330. [PubMed] [Google Scholar]
  7. Herzog Jan, Volkmann Jens, Krack Paul, Kopper Florian, Pötter Monika, Lorenz Delia, Steinbach Meike, Klebe Stefan, Hamel Wolfgang, Schrader Bettina. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord. 2003 Nov;18(11):1332–1337. doi: 10.1002/mds.10518. [DOI] [PubMed] [Google Scholar]
  8. Hilker Ruediger, Voges Juergen, Weisenbach Simon, Kalbe Elke, Burghaus Lothar, Ghaemi Mehran, Lehrke Ralph, Koulousakis Athanasios, Herholz Karl, Sturm Volker. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab. 2004 Jan;24(1):7–16. doi: 10.1097/01.WCB.0000092831.44769.09. [DOI] [PubMed] [Google Scholar]
  9. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  10. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kleiner-Fisman Galit, Fisman David N., Sime Elspeth, Saint-Cyr Jean A., Lozano Andres M., Lang Anthony E. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg. 2003 Sep;99(3):489–495. doi: 10.3171/jns.2003.99.3.0489. [DOI] [PubMed] [Google Scholar]
  12. Krack Paul, Batir Alina, Van Blercom Nadège, Chabardes Stephan, Fraix Valérie, Ardouin Claire, Koudsie Adnan, Limousin Patricia Dowsey, Benazzouz Abdelhamid, LeBas Jean François. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003 Nov 13;349(20):1925–1934. doi: 10.1056/NEJMoa035275. [DOI] [PubMed] [Google Scholar]
  13. Leenders K. L., Palmer A. J., Quinn N., Clark J. C., Firnau G., Garnett E. S., Nahmias C., Jones T., Marsden C. D. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986 Aug;49(8):853–860. doi: 10.1136/jnnp.49.8.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A. L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998 Oct 15;339(16):1105–1111. doi: 10.1056/NEJM199810153391603. [DOI] [PubMed] [Google Scholar]
  15. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., Oakes D., Seibyl J. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001 Dec 11;57(11):2089–2094. doi: 10.1212/wnl.57.11.2089. [DOI] [PubMed] [Google Scholar]
  16. Miller W. C., DeLong M. R. Parkinsonian symptomatology. An anatomical and physiological analysis. Ann N Y Acad Sci. 1988;515:287–302. doi: 10.1111/j.1749-6632.1988.tb32998.x. [DOI] [PubMed] [Google Scholar]
  17. Morrish P. K., Rakshi J. S., Bailey D. L., Sawle G. V., Brooks D. J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314–319. doi: 10.1136/jnnp.64.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Morrish P. K., Sawle G. V., Brooks D. J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996 Apr;119(Pt 2):585–591. doi: 10.1093/brain/119.2.585. [DOI] [PubMed] [Google Scholar]
  19. Morrish P. K., Sawle G. V., Brooks D. J. The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Adv Neurol. 1996;69:427–431. [PubMed] [Google Scholar]
  20. Nakao N., Nakai E., Nakai K., Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol. 1999 May;45(5):640–651. [PubMed] [Google Scholar]
  21. Nurmi E., Ruottinen H. M., Kaasinen V., Bergman J., Haaparanta M., Solin O., Rinne J. O. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol. 2000 Jun;47(6):804–808. [PubMed] [Google Scholar]
  22. Nutt John G., Carter Julie H., Lea Eric S., Sexton Gary J. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002 Jun;51(6):686–693. doi: 10.1002/ana.10189. [DOI] [PubMed] [Google Scholar]
  23. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Macias R., Alvarez L., Guridi J., Vitek J., DeLong M. R. Pathophysiologic basis of surgery for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S7–12. [PubMed] [Google Scholar]
  24. Patlak C. S., Blasberg R. G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985 Dec;5(4):584–590. doi: 10.1038/jcbfm.1985.87. [DOI] [PubMed] [Google Scholar]
  25. Piallat B., Benazzouz A., Benabid A. L. Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. J Neural Transm Suppl. 1999;55:71–77. doi: 10.1007/978-3-7091-6369-6_7. [DOI] [PubMed] [Google Scholar]
  26. Piallat B., Benazzouz A., Benabid A. L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci. 1996 Jul;8(7):1408–1414. doi: 10.1111/j.1460-9568.1996.tb01603.x. [DOI] [PubMed] [Google Scholar]
  27. Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., Würker M., Heiss W. D. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med. 1994 Dec;35(12):2011–2018. [PubMed] [Google Scholar]
  28. Rodriguez-Oroz M. C., Gorospe A., Guridi J., Ramos E., Linazasoro G., Rodriguez-Palmero M., Obeso J. A. Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S45–S51. [PubMed] [Google Scholar]
  29. Rodriguez M. C., Obeso J. A., Olanow C. W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998 Sep;44(3 Suppl 1):S175–S188. doi: 10.1002/ana.410440726. [DOI] [PubMed] [Google Scholar]
  30. Vingerhoets F. J., Snow B. J., Lee C. S., Schulzer M., Mak E., Calne D. B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994 Nov;36(5):759–764. doi: 10.1002/ana.410360512. [DOI] [PubMed] [Google Scholar]
  31. Vitek Jerrold L. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Disord. 2002;17 (Suppl 3):S69–S72. doi: 10.1002/mds.10144. [DOI] [PubMed] [Google Scholar]
  32. Voges Jürgen, Volkmann Jens, Allert Niels, Lehrke Ralph, Koulousakis Athanasios, Freund Hans-Joachim, Sturm Volker. Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. J Neurosurg. 2002 Feb;96(2):269–279. doi: 10.3171/jns.2002.96.2.0269. [DOI] [PubMed] [Google Scholar]
  33. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbauer T., Pietrzyk U., Heiss W. D. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110–118. [PubMed] [Google Scholar]
  34. Wienhard K., Eriksson L., Grootoonk S., Casey M., Pietrzyk U., Heiss W. D. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804–813. doi: 10.1097/00004728-199209000-00024. [DOI] [PubMed] [Google Scholar]
  35. Windels F., Bruet N., Poupard A., Urbain N., Chouvet G., Feuerstein C., Savasta M. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur J Neurosci. 2000 Nov;12(11):4141–4146. doi: 10.1046/j.1460-9568.2000.00296.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES